guidelines·critical care, emergency medicine, nephrology, clinical trial·PMC10226261
Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus
Military Medical Research · 45 authors, 33 centres
AI SUMMARY
FIDELITY 100%
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This guideline, developed by a Chinese expert consensus group, provides recommendations for managing regional citrate anticoagulation (RCA) during continuous renal replacement therapy (CRRT) for emergency and critically ill patients. It concludes that RCA is safer and more effective than systemic heparin anticoagulation and should be the preferred method, with specific guidance on monitoring, contraindications, and complications.
Full summary
828 CHARS
The guideline was developed by the Emergency Medical Doctor Branch of the CMDA through a systematic literature review and a Delphi consensus process involving 42 experts. It used the GRADE framework to rate evidence and formulate recommendations for managing regional citrate anticoagulation (RCA) during continuous renal replacement therapy (CRRT) in emergent and critically ill patients. The central recommendation is that RCA is the preferred anticoagulation method over systemic heparin due to a better safety and efficacy profile. The document addresses key clinical issues including patient selection, monitoring protocols, management of complications like citrate accumulation, and contraindications, noting that conditions like shock or liver dysfunction are not absolute contraindications but require closer monitoring.
